US Patent 10,292,389: Scope, Claims, and Patent Landscape
US Drug Patent 10,292,389 is a topical antimicrobial product claim set centered on a specific active ingredient, 5,5′-dimethyl-2,2′-dipyridyl (“DM-DPD”), formulated in a lotion/cream/gel matrix with defined excipients (benzyl alcohol, mineral oil, water, carbomer, trolamine, butylated hydroxytoluene, polysorbate 20). It also claims methods of treating lice via topical application, including effects tied to lice killing and egg hatching inhibition, with comparative performance language over a matched vehicle lacking DM-DPD.
What is the claimed invention in one line?
A topical aqueous lotion/gel/cream composition and lice-treatment method that uses DM-DPD at tightly defined wt% in a specific preservative/emollient/solubilizer matrix to improve lice (and ovicidal) activity versus the same excipient vehicle without DM-DPD.
Claim scope: what does the patent actually cover?
Core composition claim (independent)
Claim 1 defines a broad compositional envelope (single claim family member) using wt% ranges for each component:
| Component |
Claimed wt% range in Claim 1 |
| 5,5′-dimethyl-2,2′-dipyridyl (DM-DPD) |
0.5% to 1% |
| Benzyl alcohol |
1% to 3% |
| Mineral oil |
20% to 30% |
| Water |
60% to 90% |
| Carbomer |
0.1% to 0.5% |
| Trolamine |
0.1% to 1% |
| Butylated hydroxy toluene (BHT) |
0.2% to 1% |
| Polysorbate 20 |
0.5% to 1% |
Practical read: any topical product within these compositional ranges, with the stated excipient identities and functional role implied by the formula, lands in Claim 1. The claim is not restricted to a particular dosage form beyond being a “composition”; dependent claims then explicitly tie to lotion/cream/gel and provide preferred embodiments.
Dependent composition claims: form factor and fixed exemplars
Claim 2 narrows Claim 1 to a product type and fixed DM-DPD:
- Lotion, cream or gel
- 0.74% wt DM-DPD
Claim 3 fixes mineral oil:
- Lotion or gel
- 24% wt mineral oil
Claim 4 fixes benzyl alcohol:
- Lotion or gel
- 2% wt benzyl alcohol
These dependent claims define a typical formulation space used in prosecution and commercial embodiment targeting lice use.
Comparative-efficacy dependent claims (composition advantage language)
Two dependent claims add performance language tied to DM-DPD inclusion versus an excipient-only comparator:
Claim 5: greater lousicidal activity than a vehicle composition with the same excipients and same wt% except no DM-DPD.
Claim 6: greater ovicidal and lousicidal activity than the same matched excipient vehicle lacking DM-DPD.
Practical read: claims 5 and 6 are not just composition ranges. They introduce product-by-performance boundaries using an objective comparator defined by “same components except for DM-DPD.” That can matter in infringement analysis where a challenger attempts to argue that another formulator used the same excipients and wt% but disputes superiority.
Specific composition claim (aqueous topical formulation with a “complete recipe”)
Claim 7 is a fixed formulation “by weight” list with a balance water:
- 0.74% DM-DPD
- 24% mineral oil
- 0.15% Carbomer
- 0.20% Trolamine
- 2.00% Benzyl alcohol
- 1% Polysorbate 20
- 0.5% BHT
- Balance purified water
This claim is the strongest infringement target for a close-copy formulation because it pins exact wt% for every listed component.
Method claims: what actions are covered?
Independent method claim
Claim 8:
- A method of treating a lice infestation
- by topically applying an effective amount of a composition according to Claim 1 to a host with lice.
This is the central use claim covering both product sales and any formulator’s intended use, as long as the applied formulation fits Claim 1.
Effect refinements
Claim 9:
- Topical application kills lice and inhibits egg hatching.
Practical read: Claim 9 adds an “ovicidal/ovicidal-like” effect tied to eggs, but it does not add new chemical elements. It is an additional method-performance limitation.
Claim 10:
- Application kills more lice than a vehicle composition with the same components except for DM-DPD.
This is again a comparator framing that can be relevant both for enforceability and for non-infringement arguments focused on equivalence to the vehicle.
How tight is the chemical/formulation scope?
Active ingredient specificity
DM-DPD is the gating element across all composition and method claims. The active is explicitly 5,5′-dimethyl-2,2′-dipyridyl. Claims require it by name and tied wt% ranges (Claim 1) or fixed wt% (Claims 2, 7).
Excipients: required identities, not just functional classes
Claim 1 lists specific excipients: benzyl alcohol, mineral oil, carbomer, trolamine, BHT, polysorbate 20, plus water. That identity requirement narrows design-arounds using different preservatives, different oils, or different surfactants unless they still fall within the claim literal list.
Range breadth vs. practical substitutability
Claim 1 ranges are moderate breadth, but each one is anchored to excipient identity and wt%. The most material hinge points for infringement and design-around are:
- DM-DPD: 0.5% to 1% (Claim 1)
- Benzyl alcohol: 1% to 3%
- Mineral oil: 20% to 30%
- Carbomer: 0.1% to 0.5%
- Trolamine: 0.1% to 1%
- BHT: 0.2% to 1%
- Polysorbate 20: 0.5% to 1%
Water is “balance” within 60% to 90% by weight, which is usually determined by the sum of other components.
Design-around signal from the claim language: if a competitor shifts formulation outside at least one required wt% range for DM-DPD or another listed excipient, literal infringement of Claim 1 is disrupted. But if they remain inside the range and use the same identities, the independent claim risks coverage.
What is “vehicle” in the comparative claims, and why it matters?
Claims 5, 6, and 10 define the comparator as a composition that:
- contains benzyl alcohol, mineral oil, and polysorbate 20 at the same weight percent, but
- does not comprise DM-DPD.
The comparator described in these dependent claims is not fully specified with carbomer, trolamine, BHT, or other components. The language reads as a partial comparator, anchored to the three named excipients: benzyl alcohol, mineral oil, and polysorbate 20. That can influence how “same components except DM-DPD” is construed in practice:
- For infringement/validity fights, courts will likely treat the comparative language as a limitation requiring the claimed formulation to demonstrate superior lice/egg effects versus a substantially similar vehicle missing DM-DPD while holding at least the named excipients constant.
Business implication: if a competitor’s product excludes DM-DPD but keeps benzyl alcohol, mineral oil, and polysorbate 20 at the same wt%, they may still argue they do not fall into the “greater activity than vehicle lacking DM-DPD” limitation. If they do not exclude DM-DPD, comparative arguments lose force.
Patent landscape: where this sits and what it implies
1) What kind of IP this is
This patent is not a broad “treatment of lice” concept only. It is tightly tethered to:
- one active (DM-DPD) and
- a specific topical composition format with specific excipients and wt% ranges, and
- performance superiority claims using a vehicle comparator lacking DM-DPD.
That profile typically indicates a narrow but enforceable formulation anchor, with meaningful risk for close copycats.
2) How it likely behaves in freedom-to-operate (FTO)
Even without external document metadata, the claim set implies these FTO pressure points:
- Direct infringement risk for any product that uses DM-DPD within 0.5% to 1% and includes the listed excipients in the recited ranges.
- Higher risk for formulations matching Claim 7 exactly or close to it (0.74% DM-DPD; 24% mineral oil; 2% benzyl alcohol; 1% polysorbate 20; 0.15% carbomer; 0.20% trolamine; 0.5% BHT).
- Method claim exposure if the product is marketed/used to treat lice infestations with the claimed formulation.
- Comparative-efficacy arguments become central in disputes over “vehicle without DM-DPD” and whether the claimed formulation demonstrates superior lousicidal/ovicidal activity.
3) Landscape nodes to expect around this patent (claim-driven, not speculative)
Based on the claim theme, the closest surrounding IP risks usually fall into three buckets:
- Other DM-DPD topical compositions with different excipient sets or different wt ranges for the same components.
- Alternative actives for lice where comparative data targets the same excipients as vehicle.
- Use patents on lice treatment with topical preparations where performance claims are used to establish patentability or differentiation.
This patent’s structure (composition first, method second, and comparative superiority as dependent limits) is consistent with a formulation differentiation strategy.
Competitive differentiation and design-around map (claim-driven)
Highest protection: DM-DPD inclusion within Claim 1
- Any competitor using DM-DPD in 0.5% to 1% wt plus the other excipients in the required ranges is within the core claim set.
- A near-exact embodiment matching Claim 7 is the most immediate infringement target.
Primary design-around levers
A design-around would need to break literal scope by at least one of the following:
- Reduce or increase DM-DPD outside 0.5% to 1% (or avoid 0.74% if targeting Claims 2/7).
- Shift benzyl alcohol outside 1% to 3% or mineral oil outside 20% to 30%.
- Replace or remove required excipients (carbomer/trolamine/BHT/polysorbate 20) or shift them outside their ranges.
Because the claim uses explicit ingredient names, swapping to different excipients (even if functionally similar) may fall outside literal wording unless the substitute still matches the claimed identity list.
Comparative limitation leverage
If a competitor excludes DM-DPD but matches the vehicle excipients (benzyl alcohol, mineral oil, polysorbate 20) at similar wt%, they can argue they are outside the comparative “greater lousicidal/ovicidal activity than vehicle lacking DM-DPD” framing. If they include DM-DPD, that comparative lever is reduced.
Claim-by-claim infringement checkpoint (fast screen)
| Claim |
Coverage trigger |
Practical infringement screen |
| 1 |
Any composition meeting all listed wt ranges |
Check DM-DPD 0.5-1%, benzyl alcohol 1-3%, mineral oil 20-30%, plus the other excipients/ranges |
| 2 |
Lotion/cream/gel with 0.74% DM-DPD |
If DM-DPD exactly 0.74% and product is lotion/cream/gel |
| 3 |
Mineral oil fixed at 24% |
If mineral oil is exactly 24% within lotion/gel form |
| 4 |
Benzyl alcohol fixed at 2% |
If benzyl alcohol is exactly 2% within lotion/gel form |
| 5 |
Greater lousicidal activity vs vehicle lacking DM-DPD |
Comparative data and vehicle formulation match matter |
| 6 |
Greater ovicidal + lousicidal activity vs vehicle lacking DM-DPD |
Comparative data and vehicle formulation match matter |
| 7 |
Specific fixed recipe |
Literal match to the full wt% list and balance water |
| 8 |
Method: topical lice treatment using Claim 1 composition |
If product is applied to treat lice at an effective amount |
| 9 |
Kills lice and inhibits egg hatching |
Method outcome limitation; evidence may be required |
| 10 |
Kills more lice than vehicle lacking DM-DPD |
Comparative performance limitation |
Key Takeaways
- US 10,292,389 protects a DM-DPD topical lice composition defined by specific excipients and wt% ranges (Claim 1) plus a fixed full recipe (Claim 7).
- The method claims cover topical treatment of lice using Claim 1 compositions (Claims 8-10), with added outcome language (lice killing and egg hatching inhibition).
- The comparative dependent claims (Claims 5, 6, 10) tie enforceability to superior lousicidal/ovicidal activity versus a vehicle lacking DM-DPD while holding certain excipients constant (benzyl alcohol, mineral oil, polysorbate 20).
- From a product risk standpoint, the immediate exposure zone is any formulation using DM-DPD 0.5%-1% in the recited excipient matrix; the highest infringement risk is a product matching Claim 7 (0.74% DM-DPD, 24% mineral oil, 2% benzyl alcohol, 1% polysorbate 20, 0.15% carbomer, 0.20% trolamine, 0.5% BHT).
FAQs
1) Does Claim 1 require a specific dosage form (lotion vs gel)?
No. Claim 1 covers a “composition,” while Claims 2-4 specify lotion/cream/gel and fix certain wt% values.
2) If a competitor uses DM-DPD but outside 0.5% to 1%, do they avoid Claim 1?
Yes for literal coverage of Claim 1 because DM-DPD wt% is explicitly limited to 0.5% to 1%. However, they could still face other claims if their formulation matches those dependent fixed values.
3) Are excipients like carbomer and trolamine optional under Claim 1?
No. Claim 1 explicitly requires carbomer and trolamine within their stated wt% ranges.
4) What does the “vehicle composition” language do in Claims 5, 6, and 10?
It frames a comparator lacking DM-DPD (while anchoring benzyl alcohol, mineral oil, and polysorbate 20 at the same wt%), tying claim scope to superior lousicidal and/or ovicidal performance.
5) Which single claim is the most exact infringement target?
Claim 7, because it lists a complete formulation by weight and “balance purified water,” creating a straightforward literal match screen.
References
[1] United States Patent 10,292,389 (claims as provided in prompt).
